Navigation Links
New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly,Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer,Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by,Paclitaxel

22 US Oncology Affiliated Physicians Participate in ASCO Proceedings

HOUSTON, June 04, 2007 /PRNewswire/ -- A leading cancer researcher affiliated with the US Oncology Research Network presented findings from a randomized, multicenter phase III trial that compared the disease-free survival (DFS) obtained with two regimens of adjuvant therapy for patients with high-risk breast cancer.

The study results were given in an oral presentation by Dr. David Loesch of Central Indiana Cancer Centers, at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) held June 2-5, 2007 in Chicago. Dr. Loesch is the lead investigator and a member of US Oncology's breast cancer research committee.

The study, titled "A randomized, multicenter phase III trial comparing doxorubicin plus cyclophosphamide followed by paclitaxel or doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for high risk breast cancer" (abstract number 517) was conducted among women with local, operable, confirmed stage I-III adenocarcinoma, who had primary surgery, with no residual tumor.

The research found that Therapy Arm 2 (ATT) (doxorubicin 50 mg/m2 plus paclitaxel 200 mg/m2 repeated every three weeks for four cyclespaclitaxel 80 mg/m2 weekly x12) AT+WP can be considered equal to ACT as a standard treatment in the community. It has more peripheral neuropathy than ACT; but the neuropathy is reversible. In a repeat analysis of the triple negative subgroup, APWP was superior to ACT in overall survival (OS).

In addition, 22 physicians and researchers affiliated with US Oncology participated in oral and poster presentations, moderated panels and published studies at this year's ASCO conference in Chicago. The researchers presented findings on a variety of disease states including lung, gastrointestinal, genitourinary, gynecologic, breast and melanoma.

    -- Daniel Von Hoff, M.D.
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:9/2/2015)... , Sept. 2, 2015 China ... the "Company"), a leading fully integrated plasma-based biopharmaceutical ... announced that the Company,s subsidiary Guizhou Taibang Biological ... strategic collaboration agreement (the "Agreement") with Xinjiang Deyuan ... plasma. The Agreement allows Guizhou Taibang to source ...
(Date:9/2/2015)... 2015 Relmada Therapeutics, Inc. (OTCQB: RLMD; RLMDD), ... of chronic pain, announced today that the company,s management ... Second Annual Healthcare Conference and BioCentury NewsMakers Conference.  Details ... Second Annual Healthcare Conference Date:  Wednesday, September 9 ... No presentation, investor meetings only BioCentury ...
(Date:9/2/2015)... , Sept. 2, 2015  Kastle Therapeutics (Kastle), ... commercializing pharmaceuticals for diseases with high unmet medical ... executives to key commercial operating positions. ... President, Commercial; Sean was previously Global Marketing Director ... appointed as Director, Commercial Strategy and Analytics; Nick ...
Breaking Medicine Technology:China Biologic Enters into Strategic Collaboration Agreement to Source Raw Materials 2China Biologic Enters into Strategic Collaboration Agreement to Source Raw Materials 3China Biologic Enters into Strategic Collaboration Agreement to Source Raw Materials 4China Biologic Enters into Strategic Collaboration Agreement to Source Raw Materials 5Relmada Therapeutics to Participate in Two Upcoming Investor Conferences 2Kastle Therapeutics Announces Key Additions to Commercial Leadership 2Kastle Therapeutics Announces Key Additions to Commercial Leadership 3
... Calif., Jan. 9, 2012 Uptake Medical ® ... C funding round. The round was led by Singapore-based ... Ventures, GBS Venture Partners, WRF Capital, Arboretum Ventures and ... managing partner, will join the Uptake Medical board of ...
... Omthera Pharmaceuticals, Inc., a privately held specialty pharmaceuticals company, today ... bioavailability of Epanova ™ to Lovaza ® ... 14 days of dosing on a low fat diet, plasma ... dosed with Epanova compared to those dosed with Lovaza.  Additionally, ...
Cached Medicine Technology:Uptake Medical Announces Successful Completion of Series C Financing 2Omthera Pharmaceuticals Announces Positive Long Term Bioavailability Data Comparing Epanova™ to Lovaza® 2Omthera Pharmaceuticals Announces Positive Long Term Bioavailability Data Comparing Epanova™ to Lovaza® 3
(Date:9/2/2015)... ... September 02, 2015 , ... The 2015 ... day international investment and business conference will be hosted at five star Beijing ... The full-weekend networking conference will feature leading EB-5 industry professionals and Chinese private ...
(Date:9/2/2015)... ... September 02, 2015 , ... SonicSurg Innovations, ... market, announced today that more than 600 successful patient procedures have been performed ... Plus, nearly 70 of these procedures have been on triggering thumbs. , ...
(Date:9/2/2015)... ... ... On September 9, 2015, over 27,000 people from all over the world ... date for the state of Utah. , “We are thrilled with the overwhelming response ... doTERRA CEO. “One of the most exciting elements of our convention is the opportunity ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... PAYROLL FITNESS" and will provide two days of payroll education covering legislative updates, ... technology changes. The speakers, which include representatives from Ceridian, Ultimate Software, the American ...
(Date:9/2/2015)... ... ... Dr. Robert G. Schwartz , the principal of Piedmont Physical Medicine ... martial art system that is also a philosophy of life that focuses on reducing ... to the 10th century, is a Russian Martial Art that has four key principles ...
Breaking Medicine News(10 mins):Health News:The 2015 China Overseas Investment and Entrepreneurship Summit (COIES) Announced 2Health News:Trigger Tome Surpasses 600 Successful Patient Procedures 2Health News:doTERRA to Host the Largest Single-Company Convention in the State of Utah 2Health News:23rd Annual NJ Statewide Payroll Conference in Vernon, NJ at the Minerals Hotel on October 15-16, 2015 2Health News:Dr. Robert G. Schwartz Achieves Certification in Russian Martial Art “Systema” and Focuses on Integrating Techniques & Principles into Health Care Delivery 2Health News:Dr. Robert G. Schwartz Achieves Certification in Russian Martial Art “Systema” and Focuses on Integrating Techniques & Principles into Health Care Delivery 3
... Today, Tuesday, January 27, 2009, 9:30 A.M.** Elected ... Community Based Health System for Embracing Courageous New Direction ... Accord Includes Free and Fair Union ... Conference to announce historic hospital accords. WHEN: Today, ...
... seize billions from state, construct prison health care centers ... lawsuit was filed this week to prevent a federal ... dollars from California,s treasury for the sole purpose of ... Safe Ventura County opposes the proposal to construct seven ...
... Fitness Industry Leader Champions Gupta,s Commitment to Enriching Quality ... 27 The American Council on Exercise (ACE), America,s ... fitness certification, education and training organizations in the world, ... Dr. Sanjay Gupta , chief medical correspondent for the ...
... (NYSE: SGP ) today reported that it ... study, a pivotal Phase III study in treatment-naive patients. ... III study in patients who failed prior treatment that ... enrolled its registration studies for boceprevir, its lead investigational ...
... (NYSE Alternext US: ILI) today announced that the Company has ... "Exchange") that outlines the Company,s strategy to regain compliance with ... Exchange to formally respond to the submitted plan within 45 ... able to continue its listing up to June 23, 2010 ...
... ANTHEM, Ariz., Jan. 27 Prime Companies, Inc. ... , The Company has begun receiving income ... , The web site is now accessible ... , , "These are major achievements and ...
Cached Medicine News:Health News:Caritas Christi, 1199SEIU, Area Trades Council to Announce Historic New Accord to Improve Health Care for Community, Patients, Health Workers 2Health News:Caritas Christi, 1199SEIU, Area Trades Council to Announce Historic New Accord to Improve Health Care for Community, Patients, Health Workers 3Health News:Caritas Christi, 1199SEIU, Area Trades Council to Announce Historic New Accord to Improve Health Care for Community, Patients, Health Workers 4Health News:Caritas Christi, 1199SEIU, Area Trades Council to Announce Historic New Accord to Improve Health Care for Community, Patients, Health Workers 5Health News:Caritas Christi, 1199SEIU, Area Trades Council to Announce Historic New Accord to Improve Health Care for Community, Patients, Health Workers 6Health News:Ventura County Taxpayers' Group Files Suit to Stop State-of-the-Art Hospitals for Incarcerated Felons 2Health News:American Council on Exercise (ACE) Endorses Appointment of Dr. Sanjay Gupta as Surgeon General of the United States 2Health News:Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients 2Health News:Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients 3Health News:Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients 4Health News:Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients 5Health News:Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients 6Health News:Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients 7Health News:Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients 8Health News:Interleukin Genetics' Submits Plan to Regain Compliance with Continued Listing Standards 2Health News:Prime Companies Revenue Stream Begins; Dentists in Every City and Town Available on Company's New Web Site 2
Expressions lets you change your eye color with lenses that offer incredible comfort and outstanding vision quality. Expression color lenses use a technologically advanced tinting process to produce ...
Modern, innovative and quick Intense Pulsed Light system. The Flash 1 is light and very compact, thus easily portable. Available in two different colors....
... for the physician who wishes to offer ... of clinical applications. The innovative cooled Nd:YAG ... treaent of deeper lying veins. The IPL ... and pigmented lesions, including IPL Skin Treaents ...
Available in Purple, orange, dark blue, yellow, gray, royal blue, green and light blue colors....
Medicine Products: